We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

4 hedge funds and large institutions have $4.15M invested in Intra-Cellular Therapies Inc. in 2025 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 389 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 395 → 4 (-391)

100% less capital invested

Capital invested by funds: $13.6B → $4.15M (-$13.6B)

100% less funds holding in top 10

Funds holding in top 10: 52 → 0 (-52)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 389

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
4
Holders Change
-391
Holders Change %
-98.99%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
-52
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
2
Closed
389
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$1.26B
2
BlackRock
BlackRock
New York
-$1.15B
3
PCM
Pentwater Capital Management
Florida
-$685M
4
HI
HBK Investments
Texas
-$578M
5
Norges Bank
Norges Bank
Norway
-$472M
Name Holding Trade Value Shares
Change 		Change in
Stake
WCMNY
51
Westchester Capital Management (New York)
New York
– -$60.7M -460,267 Closed
TCA
52
Taconic Capital Advisors
New York
– -$58.5M -443,700 Closed
TS
53
Twin Securities
New York
– -$58.1M -440,690 Closed
Marshall Wace
54
Marshall Wace
United Kingdom
– -$58.1M -440,668 Closed
MF
55
Magnetar Financial
Illinois
– -$57.5M -435,715 Closed
AllianceBernstein
56
AllianceBernstein
Tennessee
– -$55.8M -423,171 Closed
MAM
57
Melqart Asset Management
United Kingdom
– -$52.9M -400,695 Closed
SSA
58
Schonfeld Strategic Advisors
New York
– -$50.4M -382,233 Closed
GL
59
Governors Lane
New York
– -$49.8M -377,737 Closed
IG
60
ING Group
Netherlands
– -$49.7M -376,800 Closed
PMAM
61
Picton Mahoney Asset Management
Ontario, Canada
– -$48.2M -365,000 Closed
Bank of New York Mellon
62
Bank of New York Mellon
New York
– -$46.2M -350,044 Closed
GF
63
Gabelli Funds
New York
– -$43M -325,700 Closed
PAMP
64
Polar Asset Management Partners
Ontario, Canada
– -$42.7M -324,020 Closed
Neuberger Berman Group
65
Neuberger Berman Group
New York
– -$42.1M -318,782 Closed
N
66
Nuveen
North Carolina
– -$40.1M -304,125 Closed
Verition Fund Management
67
Verition Fund Management
Connecticut
– -$39.8M -301,923 Closed
Adage Capital Partners
68
Adage Capital Partners
Massachusetts
– -$39.4M -298,391 Closed
UBS AM
69
UBS AM
Illinois
– -$37.5M -284,371 Closed
WA
70
Whitebox Advisors
Minnesota
– -$36.3M -275,001 Closed
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
71
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
– -$35.4M -268,000 Closed
AQR Capital Management
72
AQR Capital Management
Connecticut
– -$35.1M -266,327 Closed
SCS
73
Syquant Capital SAS
France
– -$35.1M -266,228 Closed
Franklin Resources
74
Franklin Resources
California
– -$33.7M -255,661 Closed
HSBC Holdings
75
HSBC Holdings
United Kingdom
– -$33.5M -253,660 Closed
1 2
3
4 5

ITCI Hedge Fund Activity: Q2 2025 in Review

4 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q2 2025, worth a combined $4.15M — down 100% from $13.6B a quarter earlier.

Sellers outnumbered buyers: 389 funds closed out of ITCI and 0 opened new positions — a net loss of 389 holders — while 2 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $1.26B sold.

  • 4 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q2 2025, down from 395 in Q1 2025.
  • Funds reported $4.15M of Intra-Cellular Therapies Inc. stock for Q2 2025, down 100% quarter-over-quarter.
  • 0 funds opened new Intra-Cellular Therapies Inc. positions in Q2 2025 and 389 closed out, a net change of -389 holders.
  • The largest Intra-Cellular Therapies Inc. seller in Q2 2025 was Vanguard Group, an estimated $1.26B sold.

Based on aggregated 13F filings for Q2 2025.